Loading
Us2.ai
Us2.ai is a medtech company based in Singapore, founded in 2017 by Dr. Carolyn Lam, James Hare, and Dr. Yoran Hummel. The company focuses on enhancing cardiac diagnostics through its FDA-cleared AI platform, which automates echocardiogram analysis. This platform, known as Echo Copilot, processes 2D and Doppler images quickly and accurately, generating structured clinical reports in under two minutes. The mission of Us2.ai is to make echocardiography faster, more accurate, and accessible to healthcare providers globally, ultimately improving patient outcomes. The company serves various segments, including hospital systems, clinics, and pharmaceutical companies, providing tools that enhance productivity and support clinical trials. Us2.ai's technology is designed to integrate seamlessly with existing systems, ensuring that healthcare providers can utilize it without disruption. The company is backed by notable investors and partners, reinforcing its commitment to delivering high-quality echo analysis worldwide.
Funding
Every round, secondary, debt facility or acquisition involving Us2.ai that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$3M